ALNYLAM PHARMACEUTICALS, INC.: insider trades · United States · SEC (Form 4)

About ALNYLAM PHARMACEUTICALS, INC.

Alnylam Pharmaceuticals, Inc. (ticker: ALNY) is a U.S.-listed biopharmaceutical company traded on the NASDAQ in the United States, with corporate headquarters in Cambridge, Massachusetts. Founded in 2002 by a group of leading scientists, Alnylam became the pioneer of RNA interference (RNAi) therapeutics, a gene-silencing approach designed to reduce the production of disease-causing proteins. For international equity investors, the company’s appeal lies not just in a single drug franchise but in a proprietary technology platform that has moved from scientific promise to meaningful commercial scale. Alnylam’s core business is the discovery, development, manufacturing and commercialization of siRNA-based medicines for serious and often rare diseases with substantial unmet need. The company’s marketed portfolio now centers on four key products: AMVUTTRA (vutrisiran), ONPATTRO (patisiran), GIVLAARI (givosiran) and OXLUMO (lumasiran). These therapies address important disease areas including transthyretin amyloidosis (ATTR), hereditary ATTR polyneuropathy, acute hepatic porphyria and primary hyperoxaluria type 1. In March 2025, Alnylam also secured FDA approval for Qfitlia (fitusiran), its sixth Alnylam-discovered RNAi therapeutic approved in the United States, indicated for routine prophylaxis in hemophilia A or B. That approval broadened the company’s reach beyond its established amyloidosis franchise. Competitively, Alnylam holds a leading position in RNAi therapeutics, supported by a long development track record, deep intellectual property, and expertise in oligonucleotide delivery and manufacturing. The company’s scientific differentiation is a key barrier to entry, especially in therapeutic categories where efficacy, durability and convenience matter. Its strongest commercial momentum is currently in ATTR, where AMVUTTRA has become the flagship asset. The drug is now approved in the United States, Europe and Brazil for ATTR cardiomyopathy, helping expand the addressable market and reinforcing Alnylam’s leadership in one of the most attractive rare-disease franchises in biotech. Geographically, Alnylam is increasingly global. While the United States remains its core market, the company has built a broader international footprint through sequential regulatory approvals and commercialization efforts in Europe and other regions. Recent milestones underscore the transition from development-stage biotech to commercial biotech at scale: FDA approval of AMVUTTRA for ATTR-CM in March 2025, FDA approval of Qfitlia in March 2025, European Commission approval of AMVUTTRA for ATTR-CM in June 2025, and the company’s February 2026 report of nearly $3.0 billion in 2025 net product revenues, alongside first-ever full-year GAAP and non-GAAP profitability. Taken together, these developments highlight a company with strengthening commercial leverage, expanding label breadth and a more mature financial profile.